RxDoctor Payments Data

Marcus Magnet, MD

Family Medicine · Woodbury, NJNPI 1740249457

Payments from drug & device makers

$11,587in general payments, 2019–2025

Across 785 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$994
  • Pfizer$943
  • GSK$659
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$11,44099%
  • Education$1471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,587 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$276,699
Medicare patients
655
Services billed
4,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$100,773
EliquisApixaban86$93,003
FarxigaDapagliflozin Propanediol79$90,007
JardianceEmpagliflozin48$66,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$50,305
JanuviaSitagliptin Phosphate38$45,511
MounjaroTirzepatide34$44,615
TrulicityDulaglutide25$40,762
XareltoRivaroxaban32$36,774
MyrbetriqMirabegron13$16,316
JanumetSitagliptin Phos/Metformin Hcl14$9,468
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,797
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,621
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$6,340
Atorvastatin Calcium545$6,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,205$102,352109 claims
Novo NordiskOzempic$1,490$100,77390 claims
PfizerEliquis$943$93,00386 claims
Lilly USA, LLCMounjaro, Trulicity$994$85,37759 claims
Boehringer IngelheimJardiance$259$66,84748 claims
MerckJanuvia, Janumet$38$54,97852 claims
GSKTrelegy Ellipta$659$50,30558 claims
Johnson & JohnsonXarelto$233$36,77432 claims
Astellas Pharma US IncMyrbetriq$281$16,31613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Woodbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →